Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias

REFERENCES

• Aday, J. S., C. M. Mitzkovitz, E. K. Bloesch, C. C. Davoli, and A. K. Davis. 2020. Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews 113:179–89. doi:10.1016/j.neubiorev.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. 2004. Research consent for cognitively impaired adults: Recommendations for institutional review boards and investigators. Alzheimer Disease & Associated Disorders 18 (3):171–5.
   PubMed Web of Science ®Google Scholar
• American Bar Association, Commission on Law and Aging & American Psychological Association. 2021. Assessment of older adults with diminished capacity. 2nd ed. Accessed March 27, 2022. https://www.apa.org/pi/aging/resources/guides/diminished-capacity.pdf.
   Google Scholar
• Anderson, B. T., A. Danforth, and C. Grob. 2020. Psychedelic medicine: Safety and ethical concerns. Lancet Psychiatry 7 (10):829–830.
   PubMed Web of Science ®Google Scholar
• Ankuda, C. K., D. T. Maust, M. U. Kabeto, R. J. McCammon, K. M. Langa, and D. A. Levine. 2017. Association between spousal caregiver well‐being and care recipient healthcare expenditures. Journal of the American Geriatrics Society 65 (10):2220–6. doi:10.1111/jgs.15039.
   PubMed Web of Science ®Google Scholar
• Aranda, M. P., I. N. Kremer, L. Hinton, J. Zissimopoulos, R. A. Whitmer, C. H. Hummel, L. Trejo, and C. Fabius. 2021. Impact of dementia: Health disparities, population trends, care interventions, and economic costs. Journal of the American Geriatrics Society 69 (7):1774–83. doi:10.1111/jgs.17345.
   PubMed Web of Science ®Google Scholar
• Babulal, G. M., Y. T. Quiroz, B. C. Albensi, E. Arenaza-Urquijo, A. J. Astell, C. Babiloni, A. Bahar-Fuchs, J. Bell, G. L. Bowman, A. M. Brickman, et al. 2019. Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need. Alzheimer’s & Dementia 15 (2):292–312. doi:10.1016/j.jalz.2018.09.009.
   PubMed Web of Science ®Google Scholar
• Badhwar, A., A. Tam, C. Dansereau, P. Orban, F. Hoffstaedter, and P. Bellec. 2017. Resting-state network dysfunction in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimer’s & Dementia 8:73–85. doi:10.1016/j.dadm.2017.03.007.
   Google Scholar
• Baer, D. 2019. An investing gold rush is coming for psychedelics. One line from a neuroscientist on their life-changing power explains why. Business Insider, June 2019. Accessed March 27 2022. https://www.businessinsider.com/psychedelics-gold-rush-is-coming-how-they-can-help-people-2019-6.
   Google Scholar
• Balthazar, M. L., F. R. Pereira, T. M. Lopes, E. L. da Silva, A. C. Coan, B. M. Campos, N. W. Duncan, F. Stella, G. Northoff, B. P. Damasceno, et al. 2014. Neuropsychiatric symptoms in Alzheimer’s disease are related to functional connectivity alterations in the salience network. Human Brain Mapping 35 (4):1237–46. doi:10.1002/hbm.22248.
   PubMed Web of Science ®Google Scholar
• Basting, A. D. 2003. Looking back from loss: Views of the self in Alzheimer’s disease. Journal of Aging Studies 17 (1):87–99. doi:10.1016/S0890-4065(02)00092-0.
   Web of Science ®Google Scholar
• Belouin, S. J., and J. E. Henningfield. 2018. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology 142:7–19. doi:10.1016/j.neuropharm.2018.02.018.
   PubMed Web of Science ®Google Scholar
• Brodaty, H., and M. Donkin. 2009. Family caregivers of people with dementia. Dialogues in Clinical Neuroscience 11 (2):217–28. doi:10.31887/DCNS.2009.11.2/hbrodaty.
   PubMedGoogle Scholar
• Buccafurni, D. 2004. Advance directives and the problem of personal identity. Global Virtue Ethics Review 5 (2):18–29.
   Google Scholar
• Busby, M. 2022/ Biden administration plans for legal psychedelic therapies within two years. The Intercept, July 2022. Accessed September 1, 2022. https://theintercept.com/2022/07/26/mdma-psilocybin-fda-ptsd/.
   Google Scholar
• Carhart-Harris, R. L., M. Bolstridge, C. M. J. Day, J. Rucker, R. Watts, D. E. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, et al. 2018. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology 235 (2):399–408. doi:10.1007/s00213-017-4771-x.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., and G. M. Goodwin. 2017. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 42 (11):2105–13. doi:10.1038/npp.2017.84.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., R. Leech, P. J. Hellyer, M. Shanahan, A. Feilding, E. Tagliazucchi, D. R. Chialvo, and D. Nutt. 2014. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience 8:20. doi:10.3389/fnhum.2014.00020.
   PubMed Web of Science ®Google Scholar
• Cassidy, B. 2022. Seattle’s psychedelic revolution has arrived. Seattle Metropolitan, February 2022. Accessed March 27, 2022. https://www.seattlemet.com/news-and-city-life/2022/02/seattle-psychedelic-mushrooms-decriminalization-alternative-mental-health-treatments.
   Google Scholar
• CIOMS (Council for International Organizations of Medical Sciences). 2016. International ethical guidelines for biomedical research involving human subjects. Geneva: World Health Organization. Accessed March 27, 2022. https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf.
   Google Scholar
• Cision, P. N. 2021. Ixtlan bioscience announces the filing of new patent for the psilocybin treatment of Alzheimer’s disease and brain pathologies. Cision PR Newswire, December 2021. Accessed March 27, 2022. https://www.prnewswire.com/news-releases/ixtlan-bioscience-announces-the-filing-of-new-patent-for-the-psilocybin-treatment-of-alzheimers-disease-and-brain-pathologies-301448853.html.
   Google Scholar
• Cooper, C.,. A. R. Tandy, T. B. S. Balamurali, and G. Livingston. 2010. A systematic review and meta-analysis of ethnic differences in use of dementia treatment, care, and research. The American Journal of Geriatric Psychiatry 18 (3):193–203. doi:10.1097/JGP.0b013e3181bf9caf.
   PubMed Web of Science ®Google Scholar
• Cox, D. J., A. Garcia-Romeu, and M. W. Johnson. 2021. Predicting changes in substance use following psychedelic experiences: Natural language processing of psychedelic session narratives. The American Journal of Drug and Alcohol Abuse 47 (4):444–54. doi:10.1080/00952990.2021.1910830.
   PubMed Web of Science ®Google Scholar
• DeMille, R. 1978. Castaneda’s journey: The power and allegory. London: Abacus,
   Google Scholar
• Douglass, A., and A. Ballantyne. 2019. From protectionism to inclusion: A New Zealand perspective on health‐related research involving adults incapable of giving informed consent. Bioethics 33 (3):384–92. doi:10.1111/bioe.12509.
   Web of Science ®Google Scholar
• Dresser, R. 1995. Dworkin on dementia: Elegant theory, questionable policy. The Hastings Center Report 25 (6):32–8.
   PubMed Web of Science ®Google Scholar
• Drubach, D. A. 2021. Twilight and me: A soliloquy. Continuum 27 (6):1809–17.
   PubMedGoogle Scholar
• Dubois, B., H. Hampel, H. H. Feldman, P. Scheltens, P. Aisen, S. Andrieu, H. Bakardjian, H. Benali, L. Bertram, K. Blennow, et al. 2016. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s & Dementia 12 (3):292–323. doi:10.1016/j.jalz.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Dunn, B., P. Stein, and P. Cavazzoni. 2021. Approval of aducanumab for Alzheimer disease—The FDA’s perspective. JAMA Internal Medicine 181 (10):1276–8. doi:10.1001/jamainternmed.2021.4607.
   PubMed Web of Science ®Google Scholar
• Dworkin, G. 1976. Autonomy and behavior control. The Hastings Center Report 6 (1):23–8. doi:10.2307/3560358.
   PubMed Web of Science ®Google Scholar
• Dworkin, R. 1986. Autonomy and the demented self. The Milbank Quarterly 64 (Suppl. 2):4–16. doi:10.2307/3349959.
   PubMed Web of Science ®Google Scholar
• Emanuel, E. J., D. Wendler, and C. Grady. 2000. What makes clinical research ethical? JAMA 283 (20):2701–11. doi:10.1001/jama.283.20.2701.
   PubMed Web of Science ®Google Scholar
• Etters, L., D. Goodall, and B. E. Harrison. 2008. Caregiver burden among dementia patient caregivers: A review of the literature. Journal of the American Academy of Nurse Practitioners 20 (8):423–8. doi:10.1111/j.1745-7599.2008.00342.x.
   PubMed Web of Science ®Google Scholar
• Family, N., E. L. Maillet, L. T. Williams, E. Krediet, R. L. Carhart-Harris, T. M. Williams, C. D. Nichols, D. J. Goble, and S. Raz. 2020. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237 (3):841–53. doi:10.1007/s00213-019-05417-7.
   PubMed Web of Science ®Google Scholar
• FDA (U.S. Food and Drug Administration). 2021. Watch out for false promises about so-called Alzheimer’s cures. Accessed March 27, 2022. https://www.fda.gov/consumers/consumer-updates/watch-out-false-promises-about-so-called-alzheimers-cures.
   Google Scholar
• Fikes, J. C. 1993. Carlos Castaneda, academic opportunism and the psychedelic sixties. Victoria: Millenia Press.
   Google Scholar
• Flanagan, T. W., and C. D. Nichols. 2018. Psychedelics as anti-inflammatory agents. International Review of Psychiatry 30 (4):363–75. doi:10.1080/09540261.2018.1481827.
   PubMed Web of Science ®Google Scholar
• Flanagan, T. W., M. N. Sebastian, D. M. Battaglia, T. P. Foster, E. L. Maillet, and C. D. Nichols. 2019. Activation of 5-HT 2 receptors reduces inflammation in vascular tissue and cholesterol levels in high-fat diet-fed apolipoprotein E knockout mice. Scientific Reports 9 (1):13444. doi:10.1038/s41598-019-49987-0.
   PubMedGoogle Scholar
• Fontana, A., and R. W. Smith. 1989. Alzheimer’s disease victims: The “unbecoming” of self and the normalization of competence. Sociological Perspectives 32 (1):35–46. doi:10.2307/1389006.
   Web of Science ®Google Scholar
• Forstmann, M., D. A. Yudkin, A. M. Prosser, S. M. Heller, and M. J. Crockett. 2020. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proceedings of the National Academy of Sciences of the United States of America 117 (5):2338–46. doi:10.1073/pnas.1918477117.
   PubMed Web of Science ®Google Scholar
• Friesen, P., L. Gelinas, A. Kirby, D. H. Strauss, and B. E. Bierer. 2022. IRBs and the protection-inclusion dilemma: Finding a balance. The American Journal of Bioethics :1–14. doi:10.1080/15265161.2022.2063434.
   PubMed Web of Science ®Google Scholar
• Gasser, P., K. Kirchner, and T. Passie. 2015. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology 29 (1):57–68. doi:10.1177/0269881114555249.
   PubMed Web of Science ®Google Scholar
• George, J. R., T. I. Michaels, J. Sevelius, and M. T. Williams. 2020. The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. Journal of Psychedelic Studies 4 (1):4–15. doi:10.1556/2054.2019.015.
   Google Scholar
• Gianattasio, K. Z., C. Prather, M. M. Glymour, A. Ciarleglio, and M. C. Power. 2019. Racial disparities and temporal trends in dementia misdiagnosis risk in the United States. Alzheimer’s & Dementia 5:891–8. doi:10.1016/j.trci.2019.11.008.
   Web of Science ®Google Scholar
• Gibbs, D., and T. H. Barker. 2021. A tattoo on my brain: A neurologist’s personal battle against Alzheimer’s disease. Cambridge, UK: Cambridge University Press.
   Google Scholar
• Gligorov, N., and C. Vitrano. 2011. The impact of personal identity on advance directives. The Journal of Value Inquiry 45 (2):147–58. doi:10.1007/s10790-011-9277-x.
   Web of Science ®Google Scholar
• Goldhill, O. 2022. “It’s not medical”: Oregon wrestles with how to offer psychedelics outside the health care system. STAT News, March 2022. Accessed March 27, 2022. https://www.statnews.com/2022/03/10/oregon-wrestles-with-offering-psychedelic-therapy-outside-health-care-system/.
   Google Scholar
• Goldhill, O. 2022. Psychedelic medicine group investigating a board member accused of financial elder abuse. STAT News, May 2022. Accessed August 2, 2022. https://www.statnews.com/2022/05/18/maps-psychedelics-group-investigating-board-member-accused-of-financial-elder-abuse/.
   Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Grill, J. D., C. G. Cox, K. Harkins, and J. Karlawish. 2018. Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial. Alzheimer’s Research & Therapy 10 (1):1–8. doi:10.1186/s13195-018-0452-1.
   PubMedGoogle Scholar
• Grill, J. D., and J. Karlawish. 2017. Study partners should be required in preclinical Alzheimer’s disease trials. Alzheimer’s Research & Therapy 9 (1):1–7. doi:10.1186/s13195-017-0327-x.
   PubMedGoogle Scholar
• Grill, J. D., R. Raman, K. Ernstrom, P. Aisen, and J. Karlawish. 2013. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology 80 (3):282–8. doi:10.1212/WNL.0b013e31827debfe.
   PubMed Web of Science ®Google Scholar
• Grossman, L. A. 2021. Choose your medicine: Freedom of therapeutic choice in America. Oxford: Oxford University Press.
   Google Scholar
• Hardy, J., and D. J. Selkoe. 2002. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 297 (5580):353–6. doi:10.1126/science.1072994.
   PubMed Web of Science ®Google Scholar
• Holm, S. 2001. Autonomy, authenticity, or best interest: Everyday decision-making and persons with dementia. Medicine, Health Care, and Philosophy 4 (2):153–9. doi:10.1023/a:1011402102030.
   PubMedGoogle Scholar
• Howard, R., and K. Y. Liu. 2020. Questions EMERGE as Biogen claims aducanumab turnaround. Nature Reviews Neurology 16 (2):63–4. doi:10.1038/s41582-019-0295-9.
   PubMed Web of Science ®Google Scholar
• Jack, C. R. 2020. Preclinical Alzheimer’s disease: A valid concept. The Lancet Neurology 19 (1):31. doi:10.1016/S1474-4422(19)30440-5.
   PubMed Web of Science ®Google Scholar
• Jaworska, A. 1999. Respecting the margins of agency: Alzheimer’s patients and the capacity to value. Philosophy & Public Affairs 28 (2):105–38. doi:10.1111/j.1088-4963.1999.00105.x.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., P. S. Hendricks, F. S. Barrett, and R. R. Griffiths. 2019. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics 197:83–102. doi:10.1016/j.pharmthera.2018.11.010.
   PubMed Web of Science ®Google Scholar
• Karlawish, J., S. Y. Kim, D. Knopman, C. H. van Dyck, B. D. James, and D. Marson. 2008. The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment. The American Journal of Geriatric Psychiatry 16 (3):240–7. doi:10.1097/JGP.0b013e318162992d.
   PubMed Web of Science ®Google Scholar
• Karttunen, F. E. 1992. An analytical dictionary of Nahuatl. Norman: University of Oklahoma Press.
   Google Scholar
• Kim, S. Y., H. M. Kim, K. A. Ryan, P. S. Appelbaum, D. S. Knopman, L. Damschroder, and R. De Vries. 2013. How important is ‘accuracy’ of surrogate decision-making for research participation? PLoS One 8 (1):e54790. doi:10.1371/journal.pone.0054790.
   PubMed Web of Science ®Google Scholar
• Klein, E., and J. Karlawish. 2011. Ethics of dementia care. In Principles and practice of geriatric psychiatry, eds. M. Abou-Saleh, C. L. E. Katona, and A. Kumar, 3rd ed, 410–4. Hoboken, NJ: Wiley-Blackwell.
   Google Scholar
• Kozlowska, U., C. Nichols, K. Wiatr, and M. Figiel. 2021. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. Journal of Neurochemistry. Advance online publication. doi:10.1111/jnc.15509.
   PubMed Web of Science ®Google Scholar
• Largent, E. A., M. Abera, K. Harkins, S. J. Feldman, W. R. Uhlmann, J. S. Roberts, and J. Karlawish. 2021. Family members’ perspectives on learning cognitively unimpaired older adults’ amyloid‐β PET scan results. Journal of the American Geriatrics Society 69 (11):3203–11. doi:10.1111/jgs.17362.
   PubMed Web of Science ®Google Scholar
• Largent, E. A., K. Harkins, C. H. van Dyck, S. Hachey, P. Sankar, and J. Karlawish. 2020. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLoS One 15 (2):e0229137. doi:10.1371/journal.pone.0229137.
   PubMed Web of Science ®Google Scholar
• Largent, E. A., and J. Karlawish. 2019. Preclinical Alzheimer disease and the dawn of the pre-caregiver. JAMA Neurology 76 (6):631–2. doi:10.1001/jamaneurol.2019.0165.
   PubMed Web of Science ®Google Scholar
• Largent, E. A., J. Karlawish, and J. D. Grill. 2018. Study partners: Essential collaborators in discovering treatments for Alzheimer’s disease. Alzheimer’s Research & Therapy 10 (1):1–7. doi:10.1186/s13195-018-0425-4.
   PubMedGoogle Scholar
• Largent, E. A., A. Peterson, J. Karlawish, and H. F. Lynch. 2022. Aspiring to reasonableness in accelerated approval: Anticipating and avoiding the next aducanumab. Drugs & Aging 39 (6):389–400. doi:10.1007/s40266-022-00949-8.
   PubMed Web of Science ®Google Scholar
• Largent, E. A., A. Peterson, and H. F. Lynch. 2021. FDA drug approval and the ethics of desperation. JAMA Internal Medicine 181 (12):1555–6. doi:10.1001/jamainternmed.2021.6045.
   PubMed Web of Science ®Google Scholar
• Largent, E. A., S. D. Stites, K. Harkins, and J. Karlawish. 2021. ‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with others. Journal of Law and the Biosciences 8 (1):lsab004. doi:10.1093/jlb/lsab004.
   PubMed Web of Science ®Google Scholar
• Largent, E. A., M. Terrasse, K. Harkins, D. A. Sisti, P. Sankar, and J. Karlawish. 2019. Attitudes toward physician-assisted death from individuals who learn they have an Alzheimer disease biomarker. JAMA Neurology 76 (7):864–6. doi:10.1001/jamaneurol.2019.0797.
   PubMed Web of Science ®Google Scholar
• Leggett, A. N., C. A. Polenick, D. T. Maust, and H. C. Kales. 2018. Falls and hospitalizations among persons with dementia and associated caregiver emotional difficulties. The Gerontologist 58 (2):e78–86. doi:10.1093/geront/gnx202.
   PubMed Web of Science ®Google Scholar
• Letheby, C., and P. Gerrans. 2017. Self unbound: Ego dissolution in psychedelic experience. Neuroscience of Consciousness 2017 (1):nix016. doi:10.1093/nc/nix016.
   PubMed Web of Science ®Google Scholar
• Lindsay, B. 2022. Footage of therapists spooning and pinning down patient of B.C. trial for MDMA therapy prompts review. BBC News, March 29. Accessed August 2, 2022. https://www.cbc.ca/news/canada/british-columbia/bc-mdma-therapy-videos-1.6400256.
   Google Scholar
• Lowenthal, E., and A. G. Fiks. 2016. Protecting children through research. Pediatrics 138 (4):e20162150. doi:10.1542/peds.2016-2150.
   PubMed Web of Science ®Google Scholar
• Luoma, J. B., B. Shahar, M. Kati Lear, B. Pilecki, and A. Wagner. 2021. Potential processes of change in MDMA‐assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self‐transcendence, and therapeutic relationships. Human Psychopharmacology: Clinical and Experimental 2022 May; 37(3):e2824. doi:10.1002/hup.2824.
   PubMed Web of Science ®Google Scholar
• Lynch, H. F. 2018. Opening closed doors: Promoting IRB transparency. Journal of Law, Medicine & Ethics 46 (1):145–58. doi:10.1177/1073110518766028.
   Web of Science ®Google Scholar
• Makin, S. 2018. The amyloid hypothesis on trial. Nature 559 (7715):S4–S7. doi:10.1038/d41586-018-05719-4.
   PubMed Web of Science ®Google Scholar
• Manly, J. J., and M. M. Glymour. 2021. What the aducanumab approval reveals about Alzheimer disease research. JAMA Neurology 78 (11):1305–6. doi:10.1001/jamaneurol.2021.3404.
   PubMed Web of Science ®Google Scholar
• Marschall, J., G. Fejer, P. Lempe, L. Prochazkova, M. Kuchar, K. Hajkova, and M. van Elk. 2022. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. Journal of Psychopharmacology 36 (1):97–113. doi:10.1177/02698811211050556.
   PubMed Web of Science ®Google Scholar
• Marshall, R. 2007. The dark legacy of Carlos Castaneda. Salon Magazine, April 2007. Accessed March 27, 2022. https://www.salon.com/2007/04/12/castaneda/.
   Google Scholar
• Martino, A. S., and A. F. Schormans. 2018. When good intentions backfire: University research ethics review and the intimate lives of people labeled with intellectual disabilities. Forum Qualitative: Social Research 19 (3):1–18.
   Google Scholar
• Maust, D. T., H. C. Kales, R. J. McCammon, F. C. Blow, A. Leggett, and K. M. Langa. 2017. Distress associated with dementia-related psychosis and agitation in relation to healthcare utilization and costs. The American Journal of Geriatric Psychiatry 25 (10):1074–82. doi:10.1016/j.jagp.2017.02.025.
   PubMed Web of Science ®Google Scholar
• Michaels, T. I., J. Purdon, A. Collins, and M. T. Williams. 2018. Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry 18 (1):1–4. doi:10.1186/s12888-018-1824-6.
   PubMed Web of Science ®Google Scholar
• NASEM (National Academies of Sciences, Engineering, and Medicine). 2022. Improving representation in clinical trials and research: Building research equity for women and underrepresented groups. Washington, DC: The National Academies Press. https://doi.org/10.17226/26479.
   Google Scholar
• Nielson, E. M., and J. Guss. 2018. The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies 2 (2):64–73. doi:10.1556/2054.2018.009.
   Google Scholar
• Nour, M. M., L. Evans, D. Nutt, and R. L. Carhart-Harris. 2016. Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Frontiers in Human Neuroscience 10:269. doi:10.3389/fnhum.2016.00269.
   PubMed Web of Science ®Google Scholar
• Nyholt, D. R., C. E. Yu, and P. M. Visscher. 2009. On Jim Watson’s APOE status: Genetic information is hard to hide. European Journal of Human Genetics 17 (2):147–9. doi:10.1038/ejhg.2008.198.
   PubMed Web of Science ®Google Scholar
• Olson, D. E. 2021. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science 4 (2):563–7. doi:10.1021/acsptsci.0c00192.
   PubMedGoogle Scholar
• Palop, J. J., and L. Mucke. 2016. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nature Reviews. Neuroscience 17 (12):777–92. doi:10.1038/nrn.2016.141.
   PubMed Web of Science ®Google Scholar
• Paul, L. A. 2014. Transformative experience. Oxford: Oxford University Press.
   Google Scholar
• Payne, P. 2019. Including pregnant women in clinical research: Practical guidance for institutional review boards. Ethics & Human Research 41 (6):35–40. doi:10.1002/eahr.500036.
   PubMedGoogle Scholar
• Peterson, A., and D. Sisti. 2022. Skip the trip? Five arguments on the use of nonhallucinogenic psychedelics in psychiatry. Cambridge Quarterly of Healthcare Ethics 31 (4):1–5.
   PubMedGoogle Scholar
• Phelps, J. 2017. Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology 57 (5):450–87. doi:10.1177/0022167817711304.
   Web of Science ®Google Scholar
• Pinker, S. 2009. My genome, my self. New York Times Magazine, January 2009. Accessed March 27, 2022. https://www.nytimes.com/2009/01/11/magazine/11Genome-t.html.
   Google Scholar
• Polenick, C. A., S. D. Stanz, A. N. Leggett, D. T. Maust, N. A. Hodgson, and H. C. Kales. 2020. Stressors and resources related to medication management: Associations with spousal caregivers’ role overload. The Gerontologist 60 (1):165–73. doi:10.1093/geront/gny130.
   PubMed Web of Science ®Google Scholar
• Romano, N. 2019. National Council on Disability open letter to accreditation council for genetic counseling on genetic counselor programs. National Council on Disability, December 2019. Accessed March 27, 2022. https://www.ncd.gov/publications/2019/ncd-letter-acgc-genetic-counselor-programs.
   Google Scholar
• Ross, S., A. Bossis, J. Guss, G. Agin-Liebes, T. Malone, B. Cohen, S. E. Mennenga, A. Belser, K. Kalliontzi, J. Babb, et al. 2016. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology 30 (12):1165–80. doi:10.1177/0269881116675512.
   PubMed Web of Science ®Google Scholar
• Sabat, S. R., and R. Harré. 1992. The construction and deconstruction of self in Alzheimer’s disease. Ageing & Society 12 (4):443–61.
   Google Scholar
• Saeger, H. N., and D. E. Olson. 2021. Psychedelic‐inspired approaches for treating neurodegenerative disorders. Journal of Neurochemistry. Advance online publication. doi:10.1111/jnc.15544.
   PubMed Web of Science ®Google Scholar
• Schechtman, M. 2011. Memory and identity. Philosophical Studies 153 (1):65–79. doi:10.1007/s11098-010-9645-6.
   Web of Science ®Google Scholar
• Serpico, K., V. Rahimzadeh, E. E. Anderson, L. Gelinas, and H. F. Lynch. 2022. Institutional review board use of outside experts: What do we know? Ethics & Human Research 44 (2):26–32. doi:10.1002/eahr.500121.
   PubMedGoogle Scholar
• Sessa, B. 2012. The psychedelic renaissance: Reassessing the role of psychedelic drugs in 21st century psychiatry and society. London: Muswell Hill Press.
   Google Scholar
• Shalowitz, D. I., E. Garrett-Mayer, and D. Wendler. 2006. The accuracy of surrogate decision makers: A systematic review. Archives of Internal Medicine 166 (5):493–7. doi:10.1001/archinte.166.5.493.
   PubMed Web of Science ®Google Scholar
• Smith, W. R., and P. S. Appelbaum. 2021. Two models of legalization of psychedelic substances: Reasons for concern. JAMA 326 (8):697–8. doi:10.1001/jama.2021.12481.
   PubMed Web of Science ®Google Scholar
• Tan, D. J., P. T. Hope, D. A. Stewart, and P. R. Fitzpatrick. 2006. Competence to make treatment decisions in anorexia nervosa: Thinking processes and values. Philosophy, Psychiatry, & Psychology: PPP 13 (4):267–82. doi:10.1353/ppp.2007.0032.
   PubMedGoogle Scholar
• Thorpe, C. T., N. R. Fowler, K. Harrigan, X. Zhao, Y. Kang, J. T. Hanlon, W. F. Gellad, L. J. Schleiden, and J. M. Thorpe. 2016. Racial and ethnic differences in initiation and discontinuation of Antidementia drugs by Medicare beneficiaries. Journal of the American Geriatrics Society 64 (9):1806–14. doi:10.1111/jgs.14403.
   PubMed Web of Science ®Google Scholar
• Time Magazine. 1973. Don Juan and the sorcerer’s apprentice. Time Magazine, March 1973. Accessed March 27, 2022. http://content.time.com/time/subscriber/article/0,33009,903890,00.html.
   Google Scholar
• Timmermann, C., H. Kettner, C. Letheby, L. Roseman, F. E. Rosas, and R. L. Carhart-Harris. 2021. Psychedelics alter metaphysical beliefs. Scientific Reports 11 (1):1–3. doi:10.1038/s41598-021-01209-2.
   PubMed Web of Science ®Google Scholar
• Tullis, P. 2021. How ecstasy and psilocybin are shaking up psychiatry. Nature 589 (7843):506–9. doi:10.1038/d41586-021-00187-9.
   PubMedGoogle Scholar
• Van Bruggen, V.,. P. Ten Klooster, G. Westerhof, J. Vos, E. de Kleine, E. Bohlmeijer, and G. Glas. 2017. The existential concerns questionnaire (ECQ)–development and initial validation of a new existential anxiety scale in a nonclinical and clinical sample. Journal of Clinical Psychology 73 (12):1692–703. doi:10.1002/jclp.22474.
   PubMed Web of Science ®Google Scholar
• Vann Jones, S. A., and A. O’Kelly. 2020. Psychedelics as a treatment for Alzheimer’s disease dementia. Frontiers in Synaptic Neuroscience 12:34. doi:10.3389/fnsyn.2020.00034.
   PubMed Web of Science ®Google Scholar
• Vo, T. 2022. Colorado may be the next state to decriminalize “magic” mushrooms as new research shows potential benefits. The Colorado Sun, February 2022. Accessed March 27, 2022. https://coloradosun.com/2022/02/25/mushrooms-psychedelics-legalization-attempt-colorado/.
   Google Scholar
• Wagner, A. C., R. E. Liebman, A. T. Mithoefer, M. C. Mithoefer, and C. M. Monson. 2021. Relational and growth outcomes following couples therapy with MDMA for PTSD. Frontiers in Psychiatry 12:702838. doi:10.3389/fpsyt.2021.702838.
   PubMed Web of Science ®Google Scholar
• Walsh, E. 2020. Cognitive transformation, dementia, and the moral weight of advance directives. The American Journal of Bioethics 20 (8):54–64. doi:10.1080/15265161.2020.1781955.
   PubMed Web of Science ®Google Scholar
• Webb, M., H. Copes, and P. S. Hendricks. 2019. Narrative identity, rationality, and microdosing classic psychedelics. The International Journal on Drug Policy 70:33–9. doi:10.1016/j.drugpo.2019.04.013.
   PubMed Web of Science ®Google Scholar
• Yaden, D. B., and R. R. Griffiths. 2021. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science 4 (2):568–72. doi:10.1021/acsptsci.0c00194.
   PubMedGoogle Scholar